References
- Nielsen J, Christiansen J, Lykke Andersen J et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol. Cell Biol.19, 1262–1270 (1999).
- Liao B, Hu Y, Herrick DJ et al. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J. Biol. Chem.280, 18517–18524 (2005).
- Mueller-Pillasch F, Lacher U, Wallrapp C et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene14, 2729–2733 (1997).
- Simon R, Bourne PA, Yang Q et al. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum. Pathol.38, 1178–1183 (2007).
- Hammer NA, Hansen TO, Byskov AG et al. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction130, 203–212 (2005).
- Hanley KZ, Facik MS, Bourne PA et al. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer114, 49–56 (2008).
- Pryor JG, Simon RA, Bourne PA et al. Merkel cell carcinoma expresses K homology domain-containing protein overexpressed in cancer (KOC) similar to other high-grade neuroendocrine carcinomas. Hum. Pathol. (In Press).
- Yantiss RK, Woda BA, Fanger GR et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am. J. Surg. Pathol.29, 188–195 (2005).
- Jiang Z. Prognostic biomarkers in renal cell carcinoma. Expert Rev. Mol. Diagn.7, 293–307 (2007).
- Jiang Z, Lohse CM, Chu PG et al. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer112, 2676–2682 (2008).
- Jiang Z, Chu PG, Woda BA et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol.7, 556–564 (2006).
- Li L, Xu H, Spaulding BO et al. Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum. Pathol.39, 1205–1211 (2008).
- Sitnikova L, Mendese G, Liu Q et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin. Cancer Res.14, 1701–1706 (2008).
- Yantiss RK, Cosar E, Fischer AH. Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytol.52, 133–138 (2008).
- Gu L, Shigemasa K, Ohama K. Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int. J. Oncol.24, 671–678 (2004).
- Wang T, Fan L, Watanabe Y et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br. J. Cancer88, 887–894 (2003).
- Li C, Rock KL, Woda BA et al. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod. Pathol.20, 242–247 (2007).
- Li C, Zota V, Woda BA et al. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod. Pathol.20, 1263–1268 (2007).
- Xu H, Bourne PA, Spaulding BO et al. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum. Pathol.38, 555–563 (2007).
- Pryor JG, Bourne PA, Yang Q et al. IMP 3 is a novel progression marker in malignant melanoma. Mod. Pathol.21, 431–437 (2008).
- Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res.17, 117–127 (2007).
- Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol.19, 3635–3648 (2001).